Jeffrey S. Parkin

Array ( [id] => 16870490 [patent_doc_number] => 20210163957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => NUCLEIC ACID FOR TREATING MITE ALLERGY [patent_app_type] => utility [patent_app_number] => 17/054340 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777993 [patent_doc_number] => 20190263894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/389646 [patent_app_country] => US [patent_app_date] => 2019-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16389646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15150357 [patent_doc_number] => 20190353656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION [patent_app_type] => utility [patent_app_number] => 16/386327 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16386327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712875 [patent_doc_number] => 20190247501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/370801 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977942 [patent_doc_number] => 20210222179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => RECOMBINANT BCG EXPRESSING HIV-1 P24 USING PMYONG2 VECTOR SYSTEM AND USE THEREOF AS HIV-1 VACCINE [patent_app_type] => utility [patent_app_number] => 17/055394 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598376 [patent_doc_number] => 20210024907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => NUCLEIC ACID-BASED THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/041787 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -116 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777995 [patent_doc_number] => 20190263895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => Antiretroviral Drug Targeting Human Endogenous Retrovirus [patent_app_type] => utility [patent_app_number] => 16/362193 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531443 [patent_doc_number] => 20190201342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => Protease Cleavage Site Peptides as an HIV Vaccine [patent_app_type] => utility [patent_app_number] => 16/353303 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16353303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555792 [patent_doc_number] => 20210000940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => ENGINEERED SPIKE PROTEINS OF HANTAVIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/980535 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539378 [patent_doc_number] => 20200405791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => USING INFECTIOUS NUCLEIC ACID TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 16/975782 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467813 [patent_doc_number] => 20190185549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => BROADLY CROSS-REACTIVE HIV-1-SPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV [patent_app_type] => utility [patent_app_number] => 16/291475 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8167 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134768 [patent_doc_number] => 11560421 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein [patent_app_type] => utility [patent_app_number] => 16/968470 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 15098 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 358 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18732574 [patent_doc_number] => 11801294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV) [patent_app_type] => utility [patent_app_number] => 16/267095 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 27 [patent_no_of_words] => 7324 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822771 [patent_doc_number] => 20210138064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => ANTIGEN-SURFACE-COUPLED LIPOSOME VACCINE FOR NON-HUMAN ANIMALS [patent_app_type] => utility [patent_app_number] => 16/964809 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435745 [patent_doc_number] => 20200353070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => SELECTIVE CD8-POSITIVE T CELL-INDUCING VACCINE ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/962579 [patent_app_country] => US [patent_app_date] => 2019-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868568 [patent_doc_number] => 20210162035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => Zika Vaccines and Methods of Use [patent_app_type] => utility [patent_app_number] => 16/770164 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16770164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957893 [patent_doc_number] => 20190055290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 16/177573 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227435 [patent_doc_number] => 20190125890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => Novel Scaffolded HIV-1 Vaccine Immunogens [patent_app_type] => utility [patent_app_number] => 16/177165 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929055 [patent_doc_number] => 20190048043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => Compositions and Methods Related to HIV-1 Immunogens [patent_app_type] => utility [patent_app_number] => 16/176200 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16176200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17379159 [patent_doc_number] => 11237166 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Method for detecting HIV-1-specific antibodies using clade C env polypeptides [patent_app_type] => utility [patent_app_number] => 16/174471 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 10954 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16174471 [rel_patent_id] =>[rel_patent_doc_number] =>)